Malaria transmission in Kenya ranges from intense in lowland areas to unstable epidemic-prone in the highlands. The annual reported number of malaria cases in 2021 was 4,255,874 and 753 deaths.
Malaria
Global Fund Allocation
The Global Fund announced that Kenya will receive US$392.99 million for HIV, tuberculosis, malaria, and health systems strengthening as the country allocation for 2024-2026. The Global Fund has determined the total allocation amount based on Kenya’s disease burden and income level, as well as several other factors. The malaria component is also allocated a specific proportion of the total, according to a formula developed by the Global Fund that takes into account several factors, including disease burden and previous disbursements. For Kenya this is calculated at US$ 78.6 million. The allocations to the individual disease components are not fixed, and can be adjusted according to decisions made at country level. Kenya is urged to ensure that resources are allocated to malaria control from the overall Global Fund country allocation, as well as from domestic resources, to accelerate progress. The Global Fund resources are especially important in the current resource constrained environment. The ongoing economic crisis, increased costs of doing business, and the need to introduce newer more expensive commodities to address insecticide and drug resistance mean that countries may experience shortfalls in sustaining their life-saving malaria essential services.

Progress
The country continues to work on strengthening and maintaining health services following the devastating impact of the COVID-19 pandemic. In this regard, Kenya secured the resources required to procure required ACTs and RDTs in 2023. The country has carried out insecticide resistance monitoring since 2015 and has reported the results to WHO. Kenya has completed the national insecticide resistance monitoring and management plan. Kenya has launched the Zero Malaria Starts with Me campaign. The country is implementing iCCM.

In line with the priority agenda of the ALMA chair, His Excellency President Umaro Sissoco Embaló, Kenya has significantly enhanced the tracking and accountability mechanisms for malaria with the development of a Malaria Control and Elimination Scorecard and has posted the scorecard to the ALMA Scorecard Hub. The country received the ALMA Joyce Kafanabo Award for Innovation and Excellence during the AU Summit in February 2023. The country has also launched the End Malaria Council in Q1 2021. The Kenya malaria youth army has also been launched.

Impact
The annual reported number of malaria cases in 2021 was 4,255,874 and 753 deaths.

Key Challenge
- Funding gaps to fully deliver the malaria national strategic plan.
RMNCAH and NTDs

Progress

Kenya has achieved high coverage of the tracer RMNCAH intervention vitamin A and DPT3. The country has significantly enhanced the tracking and accountability mechanisms with the development of a Reproductive, Maternal, Newborn, Child and Adolescent Health Scorecard and has published it on the scorecard hub.

Progress in addressing Neglected Tropical Diseases (NTDs) in Kenya is measured using a composite index calculated from preventive chemotherapy coverage achieved for lymphatic filariasis, schistosomiasis, soil transmitted helminths and trachoma. In 2021, preventive chemotherapy coverage was 64% for schistosomiasis, 62% for trachoma, 42% for soil transmitted helminthiasis and 0% for lymphatic filariasis. Overall, the NTD preventive chemotherapy coverage index for Kenya in 2021 is 11, which represents a substantial decrease compared with the 2020 index value of 29. The country has significantly enhanced the tracking and accountability mechanisms with the development of an NTD Scorecard.

Previous Key Recommended Actions

<table>
<thead>
<tr>
<th>Objective</th>
<th>Action Item</th>
<th>Suggested completion timeframe</th>
<th>Progress</th>
<th>Comments - key activities/accomplishments since last quarterly report</th>
</tr>
</thead>
<tbody>
<tr>
<td>Optimise quality of care</td>
<td>Work to accelerate coverage of ARTs in the total population and in children under 14 years of age</td>
<td>Q2 2023</td>
<td></td>
<td>Deliverable not yet due</td>
</tr>
<tr>
<td>NTDs</td>
<td>Recognising the negative impact of COVID-19 on the 2021 MDA coverage, work to increase the coverage of all the preventive chemotherapy NTDs</td>
<td>Q4 2023</td>
<td>[green]</td>
<td>At the end of 2022, the country conducted MDA for schistosomiasis achieving a reported coverage of 89.3% for schistosomiasis and 67.8% for STH. In Q1 2023, the country organized a workshop with different stakeholders to work on the NTD indicators integration into Kenya Health Information System. Other routine activities including surveillance are being conducted</td>
</tr>
</tbody>
</table>

Key

- Green: Action achieved
- Yellow: Some progress
- Red: No progress
- Grey: Deliverable not yet due